Sverre E. Kjeldsen

104.5k total citations · 11 hit papers
520 papers, 36.3k citations indexed

About

Sverre E. Kjeldsen is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Sverre E. Kjeldsen has authored 520 papers receiving a total of 36.3k indexed citations (citations by other indexed papers that have themselves been cited), including 414 papers in Cardiology and Cardiovascular Medicine, 150 papers in Endocrinology, Diabetes and Metabolism and 65 papers in Surgery. Recurrent topics in Sverre E. Kjeldsen's work include Blood Pressure and Hypertension Studies (316 papers), Heart Rate Variability and Autonomic Control (138 papers) and Hormonal Regulation and Hypertension (102 papers). Sverre E. Kjeldsen is often cited by papers focused on Blood Pressure and Hypertension Studies (316 papers), Heart Rate Variability and Autonomic Control (138 papers) and Hormonal Regulation and Hypertension (102 papers). Sverre E. Kjeldsen collaborates with scholars based in Norway, United States and Sweden. Sverre E. Kjeldsen's co-authors include Stevo Julius, Markku S. Nieminen, Hans Wedel, Richard B. Devereux, Björn Dahlöf, Alberto Zanchetti, Gordon T. McInnes, Gareth Beevers, Lars Lindholm and Giuseppe Mancia and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

Sverre E. Kjeldsen

502 papers receiving 34.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2007 Guidelines for the Management of Arterial Hypertension

2007 4.6k citations Giuseppe Mancia, Guıdo Grassı et al. Journal of Hypertension profile →
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

2002 3.9k citations Sverre E. Kjeldsen, Stevo Julius et al. profile →
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

2003 2.7k citations Sverre E. Kjeldsen et al. profile →
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

2005 1.9k citations Björn Dahlöf, Sverre E. Kjeldsen et al. profile →
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

2004 1.8k citations Stevo Julius, Sverre E. Kjeldsen et al. profile →
2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension

2007 1.4k citations Giuseppe Mancia, Guıdo Grassı et al. Journal of Hypertension profile →
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

2002 1.1k citations Lars Lindholm, Björn Dahlöf et al. profile →
Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

2000 650 citations Sverre E. Kjeldsen, Lars Lindholm et al. profile →
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol

2005 570 citations Kristian Wachtell, Eva Gerdts et al. profile →
Hypertension and cardiovascular risk: General aspects

2017 454 citations Sverre E. Kjeldsen profile →
Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension

2021 131 citations Gianfranco Parati, Sverre E. Kjeldsen et al. Hypertension profile →

Peers

Countries citing papers authored by Sverre E. Kjeldsen

Since Specialization

Citations

This map shows the geographic impact of Sverre E. Kjeldsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sverre E. Kjeldsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sverre E. Kjeldsen more than expected).

Fields of papers citing papers by Sverre E. Kjeldsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sverre E. Kjeldsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sverre E. Kjeldsen. The network helps show where Sverre E. Kjeldsen may publish in the future.

Co-authorship network of co-authors of Sverre E. Kjeldsen

This figure shows the co-authorship network connecting the top 25 collaborators of Sverre E. Kjeldsen. A scholar is included among the top collaborators of Sverre E. Kjeldsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sverre E. Kjeldsen. Sverre E. Kjeldsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PERSPECTIVE – The Growing Global Benefits of Limiting Salt Intake: an urgent call from the World Hypertension League for more effective policy and public health initiatives 2025 ·Journal of Human Hypertension ·Brent M. Egan, Daniel T. Lackland, Susan E. Sutherland, Michael Rakotz, Janet Williams, Yvonne Commodore‐Mensah, Daniel W. Jones, Sverre E. Kjeldsen, Norm R.C. Campbell, Gianfranco Parati, Feng J. He, Graham A. MacGregor, Michael A. Weber, Paul K. Whelton	0
2	Cardiovascular Outcomes in Hypertension-Treated Patients With Peripheral Artery Disease: The VALUE Trial 2024 ·Hypertension ·Mislav Vrsalović, (unknown), Camilla Lund Søraas, Maria H. Mehlum, Sverre E. Kjeldsen, Giuseppe Mancia, Stevo Julius, Michael A. Weber	2
3	How to optimize the use of diuretics in patients with heart failure? 2023 ·Kardiologia Polska ·Michel Burnier, Krzysztof Narkiewicz, Sverre E. Kjeldsen	2
4	The current best drug treatment for hypertensive heart failure with preserved ejection fraction 2023 ·European Journal of Internal Medicine ·(unknown), (unknown), Kristian Wachtell, Richard B. Devereux, Gerard P. Aurigemma, Otto A. Smiseth, Sverre E. Kjeldsen, Stevo Julius, Bertram Pitt, Michel Burnier, Reinhold Kreutz, Suzanne Oparil, Giuseppe Mancia, Faı̈ez Zannad	12
5	Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm Hg 2023 ·Hypertension ·(unknown), Maria H. Mehlum, Giuseppe Mancia, Camilla Lund Søraas, Knut Liestøl, Kristian Wachtell, Anne Cecilie K. Larstorp, Morten Rostrup, Julian E. Mariampillai, Sverre E. Kjeldsen, Stevo Julius, Michael A. Weber	13
6	Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines 2022 ·Hypertension ·Giuseppe Mancia, Sverre E. Kjeldsen, Reinhold Kreutz, Atul Pathak, Guıdo Grassı, Murray Esler	40
7	Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified 2022 ·Blood Pressure ·Murray Esler, Sverre E. Kjeldsen, Atul Pathak, Guıdo Grassı, Reinhold Kreutz, Giuseppe Mancia	10
8	The Oslo Ischaemia Study: cohort profile 2021 ·BMJ Open ·Ragnhild Sørum Falk, Julian E. Mariampillai, (unknown), Trond Heir, Johan Bodegård, Trude Eid Robsahm, Irene Grundvold, Per Torger Skretteberg, Kristian Engeseth, Jørgen Vildershøj Bjørnholt, Knut Stavem, Knut Liestøl, Leiv Sandvik, Erik Thaulow, Gunnar Erikssen, Sverre E. Kjeldsen, Knut Gjesdal, Jan Erikssen	1
9	Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension 2021 ·Blood Pressure ·(unknown), Björn Holzhauer, Stevo Julius, Sverre E. Kjeldsen, Anne Cecilie K. Larstorp, Giuseppe Mancia, Maria H. Mehlum, (unknown), Morten Rostrup, Camilla Lund Søraas, Dion Zappe, Michael A. Weber	3
10	Circadian variations in blood pressure and their implications for the administration of antihypertensive drugs: is dosing in the evening better than in the morning? 2020 ·Journal of Hypertension ·Michel Burnier, Reinhold Kreutz, Krzysztof Narkiewicz, Sverre E. Kjeldsen, Suzanne Oparil, Giuseppe Mancia	23
11	Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial 2016 ·Blood Pressure ·Tonje A. Aksnes, Sverre E. Kjeldsen, Morten Rostrup, Björn Holzhauer, Tsushung A. Hua, Stevo Julius	2
12	Abstract 11359: Relationship of Incident Atrial Fibrillation to the Electrocardiographic Strain Pattern in Hypertensive Patients With Electrocardiographic Left Ventricular Hypertrophy 2016 ·Circulation ·Peter M. Okin, Kristian Wachtell, Sverre E. Kjeldsen, Richard B. Devereux	1
13	Adjusted Drug Treatment Is Superior to Renal Sympathetic Denervation in Patients With True Treatment-Resistant Hypertension 2014 ·Hypertension ·Fadl Elmula M. Fadl Elmula, Pavel Hoffmann, Anne Cecilie K. Larstorp, Eigil Fossum, Magne Brekke, Sverre E. Kjeldsen, (unknown), Ulla Hjørnholm, Vibeke N. Kjær, Morten Rostrup, Ingrid Os, Aud Stenehjem, Aud Høieggen	129
14	Hyperresponders vs. nonresponder patients after renal denervation 2014 ·Journal of Hypertension ·Alexandre Persu, Michel Azizi, Yu Jin, Sebastian Völz, J. Rosa, Fadl Elmula M. Fadl Elmula, Antoinette Péchère-Bertschi, Michel Burnier, Patrick B. Mark, Arif Elvan, Jean Renkin, Marc Sapoval, Thomas Kahan, Sverre E. Kjeldsen, Jan A. Staessen	24
15	Relation Between Change in Blood Pressure in Acute Stroke and Risk of Early Adverse Events and Poor Outcome 2012 ·Stroke ·Else Charlotte Sandset, Gordon Murray, Philip M. Bath, Sverre E. Kjeldsen, Eivind Berge	42
16	Abstract 5533: Gender Differences in Outcome During Antihypertensive Therapy in Relation to Regression of Electrocardiographic Left Ventricular Hypertrophy: The LIFE Study 2009 ·Circulation ·(unknown), Eva Gerdts, Darcy A. Hille, Sverre E. Kjeldsen, (unknown), Björn Dahlöf, (unknown)	0
17	Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective 2008 ·Blood Pressure ·Sverre E. Kjeldsen, Michael A. Weber, Suzanne Oparil, Kenneth Jamerson	3
18	Abstract 4421: Concomitant Hydrochlorothiazide Therapy in Hypertensive Patients is Associated with Reduced Cardiovascular Morbidity and Mortality Independent of Blood Pressure and Electrocardiographic Left Ventricular Hypertrophy: The LIFE Study 2008 ·Circulation ·Peter M. Okin, Richard B. Devereux, Darcy A. Hille, Sverre E. Kjeldsen, Lars Lindholm, Jonathan M. Edelman, Björn Dahlöf	2
19	Effect of dopamine and dopamine-antagonist infusion on blood platelet count, size and release reaction in hypertensive and normotensive subjects 1989 ·Scandinavian Journal of Clinical and Laboratory Investigation ·Knut Lande, (unknown), Sverre E. Kjeldsen, Arne Westheim, (unknown), Lars Eide, (unknown)	3
20	Renal contribution to plasma catecholamines--effect of age. 1982 ·PubMed ·Sverre E. Kjeldsen, Ivar Eide, Carl Christensen, Arne Westheim, Ottar Müller	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact